Summarized by Masters of Longevity from Longevity Docs News.
Phase 1b trial found ruvonoflast lowered hsCRP 82% over 28 days versus 37% with placebo.
Key Takeaways
- Ruvonoflast lowered hsCRP 82% in adults with obesity.
- The trial was small, inpatient, and measured only a biomarker.
- CRP rebound within a week showed continued dosing may be needed.
